Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sentinel’s “IMPACT” Beyond Safety: Anti-Coagulant Study Is Early Test

This article was originally published in RPM Report

Executive Summary

The Sentinel post-marketing surveillance system is up and running. Now, FDA is ready to explore uses beyond safety.

You may also be interested in...



Real World Evidence Benefits, Limits Explored In US FDA Demonstrations

FDA's Jacqueline Corrigan-Curay lists three demonstrations now underway that are aimed at looking at different aspects of generating real world evidence and may inform the agency's evaluation of the data and methods.

Sentinel May Expand To Generic Equivalence Studies

Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.

Sentinel May Expand To Generic Equivalence Studies

Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel